Multiple Myeloma | Specialty

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

Quadruplet Regimens May Revolutionize Frontline Myeloma Treatment

May 11th 2021

Luciano J. Costa, MD, PhD, shares key updates regarding transplanteligible and -ineligible patients with multiple myeloma, novel triplet and quadruplet regimens that are shifting standards in the frontline setting, and other modalities under active exploration.

Selinexor With Backbone Therapy for Triple-Class Refractory Multiple Myeloma

May 11th 2021

Considerations for adding selinexor to backbone treatments for triple-class refractory multiple myeloma based on data revealed by the STOMP trial.

Establishing a Treatment Plan for Triple-Class Refractory Myeloma

May 11th 2021

Insight regarding the risk of development of triple-class refractory disease in multiple myeloma and recommendations for working with patients to establish an appropriate treatment plan and counsel on goals of therapy.

Dr. Kazandjian on Novel Therapeutic Targets in Multiple Myeloma

May 10th 2021

Dickran G. Kazandjian, MD, discusses novel therapeutic targets in multiple myeloma.

Adoption of BCMA-Directed CAR T-Cell Therapy Kickstarts A New Era in Multiple Myeloma

May 10th 2021

Nina Shah, MD, discusses the newfound role of BCMA-directed CAR T-cell therapies in multiple myeloma, how the field may select between ide-cel and cilta-cel if the latter is approved, and novel cellular therapies in clinical development.

Daratumumab-Based Triplets Translate to Improved MRD-Negative Remissions in Myeloma

May 7th 2021

Daratumumab plus lenalidomide and dexamethasone, or plus bortezomib and dexamethasone each led to higher rates of minimal residual disease negativity compared with lenalidomide plus dexamethasone or bortezomib plus dexamethasone alone in patients with relapsed/refractory multiple myeloma who were enrolled in the phase 3 POLLUX and CASTOR trials, translating to prolonged, durable remissions.

Dr. Diamond on the Rationale for Examining Long-Term MRD in Myeloma

May 5th 2021

Benjamin Diamond, MD, discusses the rationale for examining long-term minimal residual disease in patients with multiple myeloma.

Novel Triplets Shed New Light on Sequencing in Relapsed/Refractory Myeloma

May 5th 2021

New triplet combinations anchored by anti-CD38 antibodies are expanding the therapeutic landscape for relapsed or refractory multiple myeloma, providing exciting options that extend progression-free survival windows from months to years for heavily pretreated patients.

Motixafortide/G-CSF Results in 4.9-Fold Increase in Achieving Target Stem-Cell Mobilization for Transplant in Myeloma

May 4th 2021

The addition of motixafortide to granulocyte colony stimulating factor resulted in a 4.9-fold increase in achieving target stem-cell mobilization for autologous bone marrow transplantation in up to 2 apheresis sessions vs G-CSF alone in patients with multiple myeloma, meeting the primary end point of the phase 3 GENESIS trial.

Clinical Trial Diversity Efforts Gain Steam

May 4th 2021

Nearly 30 years after National Institutes of Health sought to increase participation of minorities in clinical trials, a demographic imbalance remains.

Assessing and Managing Relapsed/Refractory Myeloma

May 4th 2021

Strategies for patient assessment and treatment selection in patients with relapsed/refractory multiple myeloma.

Reduced-Dose Lenalidomide Maintenance Regimen Recommended for Elderly Patients With Myeloma

May 4th 2021

Intermediate-fit, elderly patients with newly diagnosed multiple myeloma were found to have similar outcomes with a reduced dose of lenalidomide maintenance therapy after completing 9 cycles of lenalidomide plus dexamethasone compared with standard, continuous dexamethasone.

Reacting to Relapsed/Refractory Myeloma in the Clinic

May 4th 2021

Criteria for diagnosis and risk stratification in patients with relapsed/refractory multiple myeloma.

Dr. Maura on the Challenges of Whole-Genome Sequencing in Multiple Myeloma

May 3rd 2021

Francesco Maura, MD, discusses the challenges of whole-genome sequencing in multiple myeloma.

Whole-Genome Sequencing Identifies 2 Distinct Myeloma Precursor Conditions

May 3rd 2021

Whole-genome sequencing has the potential to accurately differentiate between stable and progressive precursor conditions to multiple myeloma in low disease burden clinical states and the use of this technology in the clinic may result in a significant shift in the management of these patients.

Dr. Moreau on the FDA Approval of Isatuximab Plus Carfilzomib/Dexamethasone in Multiple Myeloma

April 28th 2021

Philippe Moreau, MD, discusses the FDA approval of isatuximab-irfc plus carfilzomib and dexamethasone in relapsed/refractory multiple myeloma.

Dr. Kazandjian on Evaluating Retreatment With BCMA-Directed Therapy in Multiple Myeloma

April 28th 2021

Dickran G. Kazandjian, MD, discusses the rationale to evaluate retreatment with BCMA-directed therapy in multiple myeloma.

Dr. Costa on Developing Later-Line Therapies for the Frontline Setting in Multiple Myeloma

April 28th 2021

Luciano J. Costa, MD, PhD, discusses the rationale to develop later-line therapies for use in the frontline setting in multiple myeloma.

Dr. Shah on the Efficacy and Safety of Cilta-Cel in Relapsed/Refractory Multiple Myeloma

April 28th 2021

Nina Shah, MD, discusses the efficacy and safety data observed with ciltacabtagene autoleucel in relapsed/refractory multiple myeloma.

Risk-Adapted Therapy Feasible in Newly Diagnosed Ultra High–Risk Myeloma

April 28th 2021

Centrally stratified risk-adapted clinical trials in patients with newly diagnosed multiple myeloma were shown to be feasible, addressing an unmet need and providing the opportunity for rapid clinical development of novel therapies.